TD Cowen analyst Steven Ma raised the firm’s price target on BioLife Solutions to $26 from $20 and keeps a Buy rating on the shares. The firm updated its model to remove CBS (freezer) revenue given the upcoming divestiture and expect Q2 execution on conservative guide and improving backdrop.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter